000 03392nam a22006017a 4500
008 191010s20192019 xxu||||| |||| 00| 0 eng d
022 _a2000-6764
024 _a10.1080/2000656X.2019.1650057 [doi]
040 _aOvid MEDLINE(R)
099 _a31478782
245 _aVenous thromboembolism in plastic surgery: the current state of evidence in risk assessment and chemoprophylactic options.
251 _aJournal of Plastic Surgery and Hand Surgery. 53(6):370-380, 2019 Dec.
252 _aJ Plast Surg Hand Surg. 53(6):370-380, 2019 Dec.
252 _zJ Plast Surg Hand Surg. :1-11, 2019 Sep 03
253 _aJournal of plastic surgery and hand surgery
260 _c2019
260 _fFY2020
265 _saheadofprint
265 _sppublish
266 _d2019-10-10
268 _aJournal of Plastic Surgery and Hand Surgery. :1-11, 2019 Sep 03
520 _aThe application of venous thromboembolism (VTE) prophylaxis has been the topic of intense debate in plastic surgery. The overall incidence of VTE is low in plastic surgery patients as compared to other surgical subspecialties but may be higher in the inpatient rather than outpatient plastic surgery populations. The Caprini Risk Assessment Model is the most highly studied and validated tool to assess VTE risk in plastic surgery patients. However, the Caprini model lacks procedure-specific risk assessment and patient-specific risk factor calculations. Due to these limitations, such as the low incidence and the heterogeneous nature of the specialty, trials lacked the power to capture proof of benefit, except in the highest-risk inpatient population. The emerging use of aspirin and novel oral anticoagulants may provide an alternative, as noninferiority in terms of efficacy and safety has been demonstrated in other fields. In this review, the authors intend to summarize the current state of evidence for prevention and explore the modalities available for prophylaxis, including novel oral anticoagulants.
546 _aEnglish
650 _a*Anticoagulants/tu [Therapeutic Use]
650 _a*Chemoprevention
650 _a*Reconstructive Surgical Procedures/ae [Adverse Effects]
650 _a*Risk Assessment
650 _a*Venous Thromboembolism/pc [Prevention & Control]
650 _aAdministration, Oral
650 _aAnticoagulants/pd [Pharmacology]
650 _aAspirin/pd [Pharmacology]
650 _aAspirin/tu [Therapeutic Use]
650 _aHeparin, Low-Molecular-Weight/pd [Pharmacology]
650 _aHeparin, Low-Molecular-Weight/tu [Therapeutic Use]
650 _aHumans
650 _aIncidence
650 _aPostoperative Complications
650 _aPyrazoles/pd [Pharmacology]
650 _aPyrazoles/tu [Therapeutic Use]
650 _aPyridones/pd [Pharmacology]
650 _aPyridones/tu [Therapeutic Use]
650 _aRivaroxaban/pd [Pharmacology]
650 _aRivaroxaban/tu [Therapeutic Use]
651 _aMedStar Health Research Institute
651 _aMedStar Washington Hospital Center
656 _aSurgery/Plastic Surgery
657 _aJournal Article
700 _aBlack, Cara K
700 _aFan, Kenneth L
790 _aAbbate O, Black CK, Camden RC, Evans KK, Fan KL, Lu K
856 _uhttps://dx.doi.org/10.1080/2000656X.2019.1650057
942 _cART
999 _c4601